Lighthouse Pharmaceuticals Raises $12 Million Series A to Advance Precision Alzheimer’s Therapy

New updates have been reported about Lighthouse Pharmaceuticals.

Lighthouse Pharmaceuticals has closed a $12 million Series A round led by Double Point Ventures, giving the clinical-stage company additional capital to advance its lead Alzheimer’s candidate, LHP588, and broaden its pipeline in neurodegenerative and inflammatory diseases. Combined with an existing $49.2 million grant from the National Institute on Aging, the financing materially strengthens Lighthouse’s ability to complete its ongoing Phase 2 SPRING trial and prepare LHP588 for potential late-stage development.

The company’s SPRING study is a randomized, double-blind, placebo-controlled Phase 2 trial in the U.S. evaluating once-daily oral LHP588 in patients with P. gingivalis–positive mild to moderate Alzheimer’s disease, reflecting Lighthouse’s strategy to focus on a biologically defined patient subset. CEO Casey Lynch said the funding and NIA support position Lighthouse to execute the trial efficiently and pursue a more precise therapeutic approach in Alzheimer’s, while Double Point Ventures partner Campbell Murray, M.D., who joins the board under this deal, highlighted the potential for SPRING data to validate an underexplored disease driver and reinforce Lighthouse’s position as an emerging innovator in neurodegeneration.